Thyroid cancer: Predisposlng conditions, growth factors, signal transduction and oncogenes

Australian and New Zealand Journal of Surgery

Volumn 68, Issue 7, 1998, Pages 469-477

  Clark, Orlo H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Growth factors and signal transduction; Oncogenes and tumour suppressor genes; Thyroid cancer

Indexed keywords

CANCER GROWTH; CANCER INVASION; GENE MUTATION; GENE REARRANGEMENT; GENETIC SUSCEPTIBILITY; ONCOGENE; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; THYROID CANCER; TUMOR SUPPRESSOR GENE; FAMILY HEALTH; GENETICS; HUMAN; METABOLISM; MUTATION; NEUROFIBROMATOSIS; PATHOLOGY; PHYSIOLOGY; SIPPLE SYNDROME; THYROID TUMOR;

ADENYLATE CYCLASE; GROWTH PROMOTOR; THYROTROPIN RECEPTOR;

ADENYLATE CYCLASE; FAMILY HEALTH; GENES, TUMOR SUPPRESSOR; GROWTH SUBSTANCES; HUMANS; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2B; MUTATION; ONCOGENES; RECEPTORS, THYROTROPIN; SIGNAL TRANSDUCTION; THYROID NEOPLASMS;

EID: 0031595114     PISSN: 00048682     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (112)

1. Hay ID, Grant CS, van Heerden JA, Oellner JR, Ebersold JR, Bergstralh EJ. Papillary thyroid microcarcinoma: A study of 535 cases observed in a 50-year period. Surgery 1992; 112: 1139-46.
2. Ain KB. Papillary thyroid carcinoma: Etiology, assessment, and therapy. Endocrinol. Metab. Clin. North Am. 1995; 24: 711-60.
3. Rosen IB, Asa SL, Brierley JO. Anaplastic carcinoma of the thyroid gland. In: Clark OH, Duh QY (eds). Textbook of Endocrine Surgery. Philadelphia: WB Saunders Co., 1997;127-32.
4. Nishiyama RH, Dunn EL, Thompson NW. Anaplastic spindle-cell and giant-cell tumors of the thyroid gland. Cancer 1972; 30: 113-27.
5. Fagin JA. Genetic basis of endocrine disease 3: Molecular defects in thyroid gland neoplasia. J. Clin. Endocrinol. Metab. 1992; 75: 1398-1400.
6. Robbins J, Menno MJ, Boice JD. Thyroid cancer, a lethal endocrine neoplasm. Ann. Intern. Med. 1991; 115: 133-45.
7. Marsh DJ, Learoyd DL, Robinson BG. Medullary thyroid carcinoma: Recent advances and management update. Thyroid 1995; 5: 407-24.
8. Wells SA Jr, Chi DD, Toshima K et al. Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A. Ann. Surg. 1994; 220: 237-50.
9. Wohllk N, Cote GJ, Evans DB, Goepfert H, Ordonez NG, Gagel RF. Application of genetic screening information to the management of medullary thyroid carcinoma and multiple endocrine neoplasia type 2. Endocrinol. Metab. Clin. North Am. 1996; 25: 1-25.
10. Haibach H, Burns TW, Carlson HE, Burman KD, Deftos LJ. Multiple hamartoma syndrome (Cowden's disease) associated with renal cell carcinoma and primary neuroendocrine carcinoma of the skin (Merkel cell carcinoma). Am. J. Clin. Pathol. 1992; 97: 705-12.
11. Nelen MR, Padberg GW, Peeters EA et al. Localization of the gene for Cowden disease to chromosome 10q22-3. Nat. Genet. 1996;13: 114-16.
12. Harach HR, Williams GT, Williams ED. Familial adenomatous polyposis associated thyroid carcinoma: A distinct type of follicular cell neoplasm. Histopathology 1994; 25: 549-61.
13. Bell B, Mazzaferri EL. Familial adenomatous polyposis (Gardner's syndrome) and thyroid carcinoma. A case report and review of the literature. Dig. Dis. Sci. 1993; 38: 185-90.
14. Zeki K, Spambalg D, Sharifi N, Gonsky R, Fagin JA. Mutations of the adenomatous polyposis coli gene in sporadic thyroid neoplasms. J. Clin. Endocrinol. Metab. 1994; 79: 1317-21.
15. Grossman RF, Tu SH, Duh QY, Siperstein AE, Novosolov F, Clark OH. Familial nonmedullary thyroid cancer: An emerging entity that warrants aggressive treatment. Arch. Surg. 1995; 130: 892-9.
16. Takami H, Ozaki O, Ito K. Familial nonmedullary thyroid cancer: An emerging entity that warrants aggressive treatment. Arch. Surg. 1996; 131: 676.
17. Loh KC. Familial nonmedullary thyroid carcinoma: A meta-review of case series. Thyroid 1997; 7: 107-13.
18. Burgess JR, Duffield A, Wilkinson SJ et al. Two families with an autosomal dominant inheritance pattern for papillary carcinoma of the thyroid. J. Clin. Endocrinol. Metabol. 1997; 82: 345-8.
19. Duffy BJ, Fitzgerald PJ. Thyroid cancer in childhood and adolescence. Cancer 1950; 3: 1018-32.
20. Winship T, Rosvoll RV. Thyroid carcinoma in childhood: Final report on a 20 year study. Clin. Proc. Children's Hospital 1970; 26: 327.
21. Thompson NW, Nishiyama RH, Harness JK. Thyroid carcinoma: Current controversies. Curr. Probl. Surg. 1978; 15: 1-67.
22. Greenspan FS. Radiation exposure and thyroid cancer. JAMA 1977; 237: 2089-91.
23. Tezelman S, Grossman RF, Siperstein AE, Clark OH. Radioiodine-associated thyroid cancers. World J. Surg. 1994; 18: 522-8.
24. Fraker DL. Factors that predispose to thyroid neoplasia. In: Clark OH, Duh QY (eds). Textbook of Endocrine Surgery. Philadelphia: WB Saunders Co., 1997; 190-6.
25. Franceschi S, Levi F, Negri E, Fassina A, La Vecchia C. Diet and thyroid cancer: A pooled analysis of four European case-control studies. Int. J. Cancer 1991; 48: 395-8.
26. Milmore JE, Chandrasekaran V, Weisburger JH. Effects of hypothyroidism on development of nitrosomethylurea-induced tumors of the mammary gland, thyroid gland, and other tissues. Proc. Soc. Exp. Biol. Med. 1982; 169: 487-93.
27. Kung TM, Ng WL, Gibson JB. Volcanoes and carcinoma of the thyroid: A possible association. Arch. Enviro. Health 1981; 36: 265-7.
28. Cohen J, Gierlowski TC, Schneider AB. A prospective study of hyperparathyroidism in individuals exposed to radiation in childhood. JAMA 1990; 264: 581-4.
29. Schneider AB, Shore-Freedman E, Weinstein RA. Radiation-induced thyroid and other head and neck tumors: Occurrence of multiple tumors and analysis of risk factors. J. Clin. Endocrinol. Metab. 1986; 63: 107-12.
30. Miller AB, Howe GR, Sherman GJ et al. Mortality from breast cancer after irradiation during fluoroscopic examinations in patients being treated for tuberculosis. N. Engl. J. Med. 1989; 321: 1285-9.
31. Nikiforov Y, Gnepp DR, Fagin JA. Thyroid lesions in children and adolescents after the Chernobyl disaster: Implications for the study of radiation tumorigenesis. J. Clin. Endocrinol. Metab. 1996; 81: 9-14.
32. Tucker MA, Jones PH, Boice JD Jr et al. Therapeutic radiation at a young age is linked to secondary thyroid cancer. The Late Effects Study Group. Cancer Res. 1991; 51: 2885-8.
33. Perkel VS, Gail MH, Lubin J et al. Radiation-induced thyroid neoplasms: Evidence for familial susceptibility factors. J. Clin. Endocrinol. Metab. 1988; 66: 1316-22.
34. Schneider AB, Gierlowski TC, Shore-Freedman E, Stovall M, Ron E, Lubin J. Dose-response relationships for radiation-induced hyperparathyroidism. J. Clin. Endocrinol. Metab. 1995; 80: 254-7.
35. Fogelfeld L, Wiviott MB, Shore-Freedman E et al. Recurrence of thyroid nodules after surgical removal in patients irradiated in childhood for benign conditions. N. Engl. J. Med. 1989; 320: 835-40.
36. Nichols CW Jr, Lindsay S, Sheline GE, Chaikoff IL. Induction of neoplasm in rat thyroid glands by x-irradiation of a single lobe. Arch. Pathol. Lab. Med. 1965; 80: 177-83.
37. DeGroot LJ. Clinical review 2: Diagnostic approach and management of patients exposed to irradiation to the thyroid. J. Clin. Endocrinol. Metab. 1989; 69: 925-8.
38. Dunhill T. Surgery of thyroid gland. Trans. Med. Soc. Lond. 1937; 60: 234-52.
39. Clark OH. TSH suppression in the management of thyroid nodules and thyroid cancer. World J. Surg. 1981; 5: 39-47.
40. Pujol P, Daures JP, Nsakala N, Baldet L, Bringer J, Jaffiol C. Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer. J. Clin. Endocrinol. Metab. 1996; 81: 4318-23.
41. Clark OH, Hoelting T. Management of patients with differentiated thyroid cancer who have positive serum thyroglobulin levels and negative radioiodine scans. Thyroid 1994; 4: 501-5.
42. Degroot LJ, Stanbury JB (eds). The Thyroid and Its Diseases. 4th edn, New York: Wiley Biomedical, 1975: 685.
43. Clark OH, Lambert WR, Amir SM, Ingbar SH. Binding of rat and bovine thyrotropin to specific sites in rat thyroid tissue. Endocrinology 1978; 103: 1805-13.
44. Clark OH, Castner BJ. Thyrotropin 'receptors' in normal and neoplastic human thyroid tissue. Surgery 1979; 85: 624-32.
45. Ichikawa Y, Saito E, Abe Y, Homma M, Muraki T. Presence of TSH receptor in thyroid neoplasms. J. Clin. Endocrinol. Metab. 1976; 42: 395-8.
46. Clark OH, Gerend PL, Goretzki P, Nissenson RA. Characterization of the thyrotropin receptor-adenylate cyclase system in neoplastic human thyroid tissue. J. Clin. Endocrinol. Metab. 1983; 57: 140-7.
47. Clark OH, Gerend PL. Thyrotropin regulation of adenylate cyclase activity in human thyroid neoplasms. Surgery 1985; 97: 539-46.
48. Gilman AG. G proteins: Transducers of receptor-generated signals. Ann. Rev. Biochem. 1987; 56: 615-49.
49. Landis CA, Masters SB, Spada A, Pace AM, Bourne HR, Vallar L. GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylate cyclase in human pituitary tumours. Nature 1989; 340: 692-6.
50. Clark OH, Gum ET, Siperstein AE, Gerend PL. Guanyl nucleotide regulatory proteins in neoplastic and normal human thyroid tissue. World J. Surg. 1988; 4: 538-45.
51. Siperstein AE, Zeng QH, Gum ET, Levin KE, Clark OH. Adenylate cyclase activity as a predictor of thyroid tumor aggressiveness. World J. Surg. 1988; 4: 528-33.
52. Zlock DW, Greenspan FS, Clark OH, Higgins CB. Octreotide therapy in advanced thyroid cancer. Thyroid 1994; 4: 427-31.
53. Shaver JK, Tezelman S, Siperstein AE, Duh QY, Clark OH. Thyroid-stimulating hormone activates phospholipase C in normal and neoplastic thyroid tissue. Surgery 1993; 114: 1064-9.
54. Ginsberg J, Murray PG. The effects of TSH receptor antibodies on protein kinase C in the thyroid. Clin. Endocrinol. 1993; 38: 45-8.
55. Van Sande J, Raspe E, Perret J, Lejeune C et al. Thyrotropin activates both the cyclic AMP and the PIP2 cascades in CHO cells expressing the human cDNA of TSH receptor. Mol. Cell. Endocrinol. 1990; 74: R1-6.
56. Belfiore A, Garofalo MR, Giuffrida D et al. Increased aggressiveness of thyroid cancer in patients with Graves' disease. J. Clin. Endocrinol. Metab. 1990; 70: 830-5.
57. Williams DW, Williams ED, Wynford-Thomas D. Loss of dependence on IGF-1 for proliferation of human thyroid adenoma cells. Br. J. Cancer 1988; 57: 535-9.
58. Roger PP, Dumont JE. Factors controlling proliferation and differentiation of canine thyroid cells cultured in reduced serum conditions: Effects of thyrotropin, cyclic AMP and growth factors. Mol. Cell. Endocrinol. 1984; 36: 79-93.
59. Westermark K, Karlsson FA, Westermark B. Epidermal growth factor modulates thyroid growth and function in culture. Endocrinology 1983; 112: 1680-6.
60. Duh QY, Gum ET, Gerend PL, Raper SE, Clark OH. Epidermal growth factor receptors in normal and neoplastic thyroid tissue. Surgery 1985; 98: 1000-7.
61. Holting T, Zielke A, Siperstein AE, Clark OH, Duh QY. Transforming growth factor-beta 1 is a negative regulator for differentiated thyroid cancer: Studies of growth, migration, invasion, and adhesion of cultured follicular and papillary thyroid cancer cell lines. J. Clin. Endocrinol. Metab. 1994; 79: 806-13.
62. Hoelting T, Siperstein AE, Duh QY, Clark OH. Tamoxifen inhibits growth, migration, and invasion of human follicular and papillary thyroid cancer cells in vitro and in vivo. J. Clin. Endocrinol. Metab. 1995; 80: 308-13.
63. Russo D, Tumino S, Arturi F et al. Detection of an activating mutation of the thyrotropin receptor in a case of an autonomously hyperfunctioning thyroid insular carcinoma. J. Clin. Endocrinol. Metab. 1997; 82: 735-8.
64. Lemoine NR, Mayall ES, Wyllie FS et al. Activated ras oncogenes in human thyroid cancers. Cancer Research 1988; 48: 4459-63.
65. Lyons J, Landis CA, Harsh G et al. Two G protein oncogenes in human endocrine tumors. Science 1990; 249: 655-9.
66. Bongarzone I, Pierotti MA, Monzini N et al. High frequency of activation of tyrosine kinase oncogenes in human papillary thyroid carcinoma. Oncogene 1989; 4: 1457-62.
67. Santoro M, Sabino N, Ishizaka Y et al. Involvement of RET oncogene in human tumours: Specificity of RET activation to thyroid tumours. Br. J. Cancer 1993; 68: 460-4.
68. Greco A, Pierotti MA, Bongarzone I, Pagliardini S, Lanzi C, Della Porta G. TRK-T1 is a novel oncogene formed by the fusion of TPR and TRK genes in human papillary thyroid carcinomas. Oncogene 1992; 7: 237-42.
69. Pierotti MA, Bongarzone I, Borrello MG et al. Rearrangements of TRK proto-oncogene in papillary thyroid carcinomas. J. Endocrinol. Invest. 1995; 18: 130-3.
70. Di Renzo MF, Olivero M, Serini G et al. Overexpression of the c-MET/HGF receptor in human thyroid carcinomas derived from the follicular epithelium. J. Endocrinol. Invest. 1995; 18: 134-9.
71. Jones CJ, Shaw JJ, Wyllie FS, Gaillard N, Schlumberger M, Wynford-Thomas D. High frequency deletion of the tumour suppressor gene P16INK4a (MTS1) in human thyroid cancer cell lines. Mol. Cell. Endocrinol. 1996; 116: 115-19.
72. Tung WS, Shevlin DW, Bartsch D, Norton JA, Wells SA Jr, Goodfellow PJ. Infrequent CDKN2 mutation in human differentiated thyroid cancers. Mol. Carcinog. 1996; 15: 5-10.
73. Fagin JA, Matsuo K, Karmakar A, Chen DL, Tang SH, Koeffler HP. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J. Clin. Invest. 1993; 91: 179-84.
74. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759-67.
75. Lemoine NR, Mayall ES, Wyllie FS et al. Activated ras oncogenes in human thyroid cancers. Cancer Res. 1988; 48: 4459-63.
76. Wright PA, Williams ED, Lemoine NR, Wynford-Thomas D. Radiation-associated and 'spontaneous' human thyroid carcinomas show a different pattern of ras oncogene mutation. Oncogene 1991; 6: 471-3.
77. Namba H, Gutman RA, Matsuo K, Alvarez A, Fagin JA. H-ras protooncogene mutations in human thyroid neoplasms. J. Clin. Endocrinol. Metab. 1990; 71: 223-9.
78. Barbacid M. Ras genes. Ann. Rev. Biochem. 1987; 56: 779-827.
79. Wright PA, Lemoine NR, Mayall ES et al. Papillary and follicular thyroid carcinomas show a different pattern of ras oncogene mutation. Br. J. Cancer 1989; 60: 576-7.
80. Sarne D, Schneider AB. External radiation and thyroid neoplasia. Endocrinol. Metab. Clin. North Am. 1996; 25: 181-95.
81. Dagny R, Faksvag Haugen DR, Lillehaug JR, Akslen LA. Enhanced expression of EGF receptor and low frequency of ras mutation in x-ray-induced rat thyroid tumors. PhD thesis, University of Bergen, Norway, 1996.
82. Challeton C, Bounacer A, Du Villard JA, et al. Pattern of ras and gsp oncogene mutations in radiation-associated human thyroid tumors. Oncogene 1995; 11: 601-3.
83. Shi YF, Zou MJ, Schmidt H et al. High rates of ras codon 61 mutation in thyroid tumors in an iodide-deficient area. Cancer Res. 1991; 51: 2690-3.
84. Goretzki PE, Lyons J, Stacy-Phipps S et al. Mutational activation of RAS and GSP oncogenes in differentiated thyroid cancer and their biological implications. World J. Surg. 1992; 16: 576-82.
85. Hara H, Fulton N, Yashiro T, Ito K, DeGroot LJ, Kaplan EL. N-ras mutation: An independent prognostic factor for aggressiveness of papillary thyroid carcinoma. Surgery 1994; 116: 1010-16.
86. Manenti G, Pilotti S, Re FC, Della Porta G, Pierotti MA. Selective activation of ras oncogenes in follicular and undifferentiated thyroid carcinomas. Eur. J. Cancer 1994; 30A: 987-93.
87. Basolo F, Pinchera A, Fugazzola L et al. Expression of p21 ras protein as a prognostic factor in papillary thyroid cancer. Eur. J. Cancer 1994; 30A: 171-4.
88. Vallar L, Spada A, Giannattasio G. Altered Gs and adenylate cyclase activity in human GH-secreting pituitary adenomas. Nature 1987; 330: 566-8.
89. O'Sullivan C, Barton CM, Staddon SL, Brown CL, Lemoine NR. Activating point mutations of the gsp oncogene in human thyroid adenomas. Mol. Carcinog. 1991; 4: 345-9.
90. Suarez HG, du Villard JA, Caillou B, Schlumberger M, Parmentier C, Monier R. Gsp mutations in human thyroid tumours. Oncogene 1991; 6: 677-9.
91. Carlson KM, Dou S, Chi D et al. Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B. Proc. Nat. Acad. Sci. USA 1994; 91: 1579-83.
92. Zedenius J, Wallin G, Hamberger B, Nordenskjold M, Weber G, Larsson C. Somatic and MEN 2A de novo mutations identified in the RET proto-oncogene by screening of sporadic MTCs. Hum. Mol. Genet. 1994; 3: 1259-62.
93. Eng C, Mulligan LM, Smith DP et al. Mutation of the RET protooncogene in sporadic medullary thyroid carcinoma. Genes Chromosomes Cancer 1995; 12: 209-12.
94. Schuffenecker I, Ginet N, Goldgar D et al. Prevalence and parental origin of de novo ret mutations in multiple endocrine neoplasia type 2A and familial medullary thyroid carcinoma. Le Groupe d'Etude des Tumeurs a Calcitonine. Am. J. Hum. Genet. 1997; 60: 233-7.
95. Grieco M, Santoro M, Berlingieri MT et al. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell 1990; 60: 557-63.
96. Sozzi G, Pierotti MA, Miozzo M et al. Refined localization to contiguous regions on chromosome 10q of the two genes (H4 and RET) that form the oncogenic sequence PTC. Oncogene 1991; 6: 339-42.
97. Pierotti MA, Santoro M, Jenkins RB et al. Characterization of an inversion on the long arm of chromosome 10 juxtaposing D10S170 and RET and creating the oncogenic sequence RET/PTC. Proc. Nat. Acad. Sci. USA 1992; 89: 1616-20.
98. Santoro M, Dathan NA, Berlingieri MT et al. Molecular characterization of RET/PTC3: A novel rearranged version of the RET proto-oncogene in a human thyroid papillary carcinoma. Oncogene 1994; 9: 509-16.
99. Sugg SL, Zheng L, Rosen IB, Freeman JL, Ezzat S, Asa SL. ret/PTC-1, -2, and -3 oncogene rearrangements in human thyroid carcinomas: Implications for metastatic potential? J. Clin. Endocrinol. Metab. 1996; 81: 3360-5.
100. Jhiang SM, Fithian L, Weghorst CM et al. RET mutation screening in MEN2 patients and discovery of a novel mutation in a sporadic medullary thyroid carcinoma. Thyroid 1996; 6: 115-21.
101. Ito T, Seyama T, Iwamoto KS et al. In vitro irradiation is able to cause RET oncogene rearrangement. Cancer Res. 1993; 53: 2940-3.
102. Klein R, Jing SQ, Nanduri V, O'Rourke E, Barbacid M. The trk proto-oncogene encodes a receptor for nerve growth factor. Cell 1991; 65: 189-97.
103. Bottaro DP, Rubin JS, Faletto DL et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991; 251: 802-4.
104. Haugen DRF. Growth Factor Receptors in Thyroid Cancer. Norway: Bergen, 1996: 8.
105. Jones CJ, Shaw JJ, Wyllie FS, Gaillard N, Schlumberger M, Wynford-Thomas D. High frequency deletion of the tumour suppressor gene P16INK4a (MTS1) in human thyroid cancer cell lines. Mol. Cell. Endocrinol. 1996; 116: 115-19.
106. Ito T, Seyama T, Mizuno T et al. Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland. Cancer Res. 1992; 52: 1369-71.
107. Holm R, Nesland JM. Retinoblastoma and p53 tumour suppressor gene protein expression in carcinomas of the thyroid gland. J. Pathol. 1994; 172: 267-72.
108. Donghi R, Longoni A, Pilotti S, Michieli P, Della Porta G, Pierotti MA. Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. J. Clin. Invest. 1993; 91: 1753-60.
109. Fand NR, Shi Y, Zou M. Molecular basis of thyroid cancer. Endocr. Rev. 1994; 15: 202-32.
110. Jossart GH, Epstein HD, Shaver JK et al. Immunocytochemical detection of p53 in human thyroid carcinomas is associated with mutation and immortalization of cell lines. J. Clin. Endocrinol. Metab. 1996; 81: 3498-504.
111. Dobashi Y, Sugimura H, Sakamoto A et al. Stepwise participation of p53 gene mutation during dedifferentiation of human thyroid carcinomas. Diag. Mol. Pathol. 1994; 3: 9-14.
112. Fogelfeld L, Bauer TK, Schneider AB, Swartz JE, Zitman R. p53 gene mutations in radiation-induced thyroid cancer. J. Clin. Endocrinol. Metab. 1996; 81: 3039-44.